The country of origin of Norethindrone Acetate/Ethinyl Estradiol (NDAc/EE) Tablets
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- In this case, we find the mixing of the active ingredients Norethindrone Acetate (made in Netherlands) and Ethinyl Estradiol (made in Netherlands) with the inactive ingredients into the final dosage tablets in China results in a substantial transformation and the country of origin will be China.
Ruling text
In your letter dated September 3, 2025, you requested a country of origin ruling on Norethindrone Acetate/Ethinyl Estradiol (NDAc/EE) Tablets. Norethindrone Acetate/Ethinyl Estradiol (NDAc/EE) Tablets, is a fixed-dose oral contraceptive containing a combination of Norethindrone Acetate (a progestin) and Ethinyl Estradiol (a steroidal estrogen), as the active ingredients. It is indicated for the prevention of pregnancy.
You stated that the active pharmaceutical ingredients (APIs), Norethindrone Acetate and Ethinyl Estradiol, are manufactured in the Netherlands. The finished tablets in dosage form are manufactured in China. In China, the Norethindrone Acetate and Ethinyl Estradiol APIs will be mixed with various inactive ingredients to produce the final tablets in dosage form. You indicated there is no substantial transformation of either of the two APIs when processed into the final dosage form. As explained below, we disagree.
Section 134.1(b), Customs Regulations (19 CFR 134.1(b)), defines "country of origin" as: The country of manufacture, production or growth of any article of foreign origin entering the United States. Further work or material added to an article in another country must effect a substantial transformation in order to render such other country the "country of origin" within the meaning of this part; ….
A substantial transformation occurs when an article emerges from a process with a new name, character or use different from that possessed by the article prior to processing. A substantial transformation will not result from a minor manufacturing or combining process that leaves the identity of the article intact. See United States v. Gibson-Thomsen Co., 27 C.C.P.A. 267 (1940); and National Juice Products Association v. United States, 628 F. Supp. 978 (Ct. Int’l Trade 1986).
In determining whether a substantial transformation occurs in the manufacture of chemical products such as pharmaceuticals, CBP has consistently examined the complexity of the processing and whether the final article retains the essential identity and character of the raw material. To that end, CBP has generally held that the processing of pharmaceutical products from bulk form into measured doses does not result in a substantial transformation of the product.
See, e.g., Headquarters Ruling (“HQ”) 561975, dated April 3, 2002; HQ 561544, dated May 1, 2000; HQ 735146, dated November 15, 1993; HQ H267177, dated November 5, 2016; HQ H233356, dated December 26, 2012; and, HQ 561975, dated April 3, 2002. However, where the processing from bulk form into measured doses involves the combination of two or more APIs, and the resulting combination offers additional medicinal benefits compared to taking each API alone, CBP has held that a substantial transformation occurred.
See, e.g., HQ 563207, dated June 1, 2005. In this instance we note that the two APIs serve different purposes. Here, as in HQ 563207, two separate APIs are mixed to create a fixed combination drug that offers additional medicinal benefits compared to taking each API alone.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N353195).